ACM Biolabs Announces Positive Topline Results from a Phase I Trial of SARS-CoV-2 Booster Vaccine ACM-001
- Written by PR Newswire Asia - News Pronto RSS
- Provides clinical validation for ACM Biolab's Tunable Platform ("ATP™"), ACM Biolab's proprietary polymer-based delivery platform
- ACM-001 was well tolerated at the recommended dose levels with no serious adverse events and encouraging early immunogenicity data
- ACM is in partnering discussions to provide new drug delivery...